阿奇霉素序贯治疗小儿支原体肺炎的系统评价

System Evaluation of Azithromycin Sequential Treatment of Mycoplasma Pneumonia in Children

关键词:  阿奇霉素  序贯治疗  支原体肺炎  系统评价

Key words:  azithromycin  sequential therapy  mycoplasma pneumonia  system evaluation

摘要:

目的 系统评价阿奇霉素序贯治疗小儿支原体肺炎的临床有效性和安全性。方法 采用计算机和手工检索相结合的方法，检索2005年1月—2012年9月国内公开发表的有关阿奇霉素序贯治疗小儿支原体肺炎的相关文献，采用RevMan5.0对符合条件的文献进行Meta分析。结果 共有9篇文献，737例患者满足纳入标准。合并分析结果显示，临床有效率方面的比数比(OR)为3.87，95%可信区间(CI)为(2.23~6.71)；不良反应发生率方面的OR为0.16，95% CI为(0.11~ 0.24)。结论 阿奇霉素序贯治疗小儿支原体肺炎的临床有效率优于对照组，且不良反应少于对照组。

Abstract:

OBJECTIVE To evaluate the clinical efficacy and safety of azithromycin sequential treatment of mycoplasma pneumonia in children. METHODS Combination of computer and manual search was used. The relevant references on the effect of azithromycin sequential treatment of mycoplasma pneumonia in children which were published from 2005.1 to 2012.9 in China were explored, and Meta-analysis was taken on the qualified references. RESULTS Nine references including 737 patients met inclusion criteria. The systematic review showed that the total effective rate combined OR were 3.87, 95% CI was (2.23-6.71). The incidence of adverse drug reaction combined OR were 0.16, 95% CI was (0.11-0.24). CONCLSUSION The effect of azithromycin sequential treatment of mycoplasma pneumonia in children is better than that in control group. And the adverse reactions is less than the control group.